Does Rallies show Form 4 insider transactions for MDGL?

Yes. Rallies tracks MDGL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MDGL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MDGL. It does not provide personalized investment advice.

MDGL (Madrigal Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a publicly traded Healthcare sector company. As of May 21, 2026, MDGL trades at $513.47 with a market cap of $12.04B and a P/E ratio of -39.89. MDGL moved +0.31% today. Year to date, MDGL is -12.73%; over the trailing twelve months it is +75.39%. Its 52-week range spans $200.63 to $615.00. Analyst consensus is strong buy with an average price target of $674.25. Rallies surfaces MDGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MDGL stock inside the company?

Recent MDGL insider activity includes Soergel David sold 844, Dier Mardi sold 646, Dier Mardi sold 40, Dier Mardi sold 420, and Dier Mardi sold 80. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MDGL Key Metrics

Key financial metrics for MDGL
Metric	Value
Price	$513.47
Market Cap	$12.04B
P/E Ratio	-39.89
EPS	$-12.85
Dividend Yield	0.00%
52-Week High	$615.00
52-Week Low	$200.63
Volume	0
Avg Volume	0
Revenue (TTM)	$958.40M
Net Income	$-288.28M
Gross Margin	0.00%

Recent MDGL Insider Trades

Soergel David sold 844 (~$435.42K) on May 18, 2026.
Dier Mardi sold 646 (~$279.03K) on Mar 6, 2026.
Dier Mardi sold 40 (~$17.00K) on Mar 6, 2026.
Dier Mardi sold 420 (~$179.28K) on Mar 6, 2026.
Dier Mardi sold 80 (~$34.23K) on Mar 6, 2026.

Latest MDGL News

Madrigal jumps as Q1 revenue hits $311M on strong Rezdiffra uptake — May 6, 2026
Madrigal (MDGL) slides ahead of May 6 Q1 earnings, traders de-risk — May 5, 2026
Madrigal Secures ARO-PNPLA3 siRNA License with $25M Upfront, 46% Fat Reduction Data — May 5, 2026
Madrigal slides 3% as traders fade recent strength amid Rezdiffra margin focus — Apr 7, 2026
MDGL ticks higher as Rezdiffra sales momentum and 2026 outlook stay in focus — Apr 2, 2026

MDGL Analyst Consensus

8 analysts cover MDGL: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $674.25.

Common questions about MDGL

Who is trading MDGL stock inside the company?: Recent MDGL insider activity includes Soergel David sold 844, Dier Mardi sold 646, Dier Mardi sold 40, Dier Mardi sold 420, and Dier Mardi sold 80. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MDGL?: Yes. Rallies tracks MDGL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MDGL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MDGL. It does not provide personalized investment advice.